Zobrazeno 1 - 10
of 339
pro vyhledávání: '"Krishnansu S, Tewari"'
Publikováno v:
Gynecologic Oncology Reports, Vol 48, Iss , Pp S35- (2023)
Objectives: Chemotherapy-induced alopecia represents a significant patient concern. The DigniCapTM Scalp Cooling Device is not covered by health insurance and patients pay out of pocket for each chemotherapy infusion. Previous reports comprised of he
Externí odkaz:
https://doaj.org/article/1faed53d2bad40c5a6ee381fdc6481a0
Autor:
Michael T. Richardson MD, Kristopher Attwood PhD, Gabriella Smith MD, Su-Ying Liang PhD, Katherine LaVigne Mager MD, Krishnansu S. Tewari MD, Robert L. Coleman MD, Daniel S. Kapp PhD, MD, John K. Chan MD, Bradley J. Monk MD
Publikováno v:
Cancer Control, Vol 30 (2023)
Objectives To evaluate outcomes and cost-effectiveness of targeted therapy sequencing for metastatic and recurrent cervical cancer. Method Models were simulated based on phase II and III trials on bevacizumab (bev) from GOG-240, cemiplimab (cemi) fro
Externí odkaz:
https://doaj.org/article/74119d2931d847cfaddaa87542207ad4
Autor:
Erin E. Hahn, Corrine Munoz-Plaza, Danielle E. Altman, Chunyi Hsu, Nancy T. Cannizzaro, Quyen Ngo-Metzger, Patricia Wride, Michael K. Gould, Brian S. Mittman, Melissa Hodeib, Krishnansu S. Tewari, Lena H. Ajamian, Ramez N. Eskander, Devansu Tewari, Chun R. Chao
Publikováno v:
Implementation Science Communications, Vol 2, Iss 1, Pp 1-14 (2021)
Abstract Background New cervical cancer screening guidelines recommend primary human papillomavirus (HPV) testing for women age 30–65 years. Healthcare organizations are preparing to de-implement the previous recommended strategies of Pap testing o
Externí odkaz:
https://doaj.org/article/13b304f25007491ba8625f49c5df3655
Autor:
Tiffany Y. Sia, William P. Tew, Christopher Purdy, Dennis S. Chi, Andrew W. Menzin, John L. Lovecchio, Michael A. Bookman, David E. Cohn, Deanna G. Teoh, Michael Friedlander, David Bender, David G. Mutch, David M. Gershenson, Krishnansu S. Tewari, Robert M. Wenham, Andrea E. Wahner Hendrickson, Roger B. Lee, Heidi J. Gray, Angeles Alvarez Secord, Linda Van Le, Stuart M. Lichtman
Publikováno v:
Gynecologic Oncology. 173:130-137
Publikováno v:
Gynecologic Oncology Reports, Vol 29, Iss , Pp 40-47 (2019)
Cervical cancer is the most common cancer in Tanzania. After excluding human immunodeficiency virus, lower respiratory infections, malaria, diarrheal diseases, and tuberculosis, cervical cancer kills more women than any other form of illness in the c
Externí odkaz:
https://doaj.org/article/2395a759f3854f08a88fb3b700369fbc
Autor:
Marisa C Liu, Krishnansu S Tewari
Publikováno v:
Drugs in Context, Vol 7, Pp 1-9 (2018)
Over the last decade, new therapeutics in the form of anti-angiogenic treatment, synthetic lethality, and checkpoint inhibition have offered new options for the treatment of ovarian cancer. This review summarizes studies related to these treatment mo
Externí odkaz:
https://doaj.org/article/1fc5bdf633104df1a16c915a36c7ca42
Autor:
Thomas J. Herzog, Sandro Pignata, Sharad A. Ghamande, Maria-Jesús Rubio, Keiichi Fujiwara, Christof Vulsteke, Deborah K. Armstrong, Jalid Sehouli, Robert L. Coleman, Hani Gabra, Giovanni Scambia, Bradley J. Monk, José A. Arranz, Kimio Ushijima, Rabbie Hanna, Claudio Zamagni, Robert M. Wenham, Antionio González-Martín, Brian Slomovitz, Yan Jia, Lisa Ramsay, Krishnansu S. Tewari, Susan C. Weil, Ignace B. Vergote
Publikováno v:
Gynecologic oncology
Objective. The primary purpose of this study was to determine if farletuzumab, an antifolate receptor-alpha monoclonal antibody, improved progression-free survival (PFS) versus placebo when added to standard chemo-therapy regimens in patients with pl
Autor:
Larry J. Copeland, Mark F. Brady, Robert A. Burger, William H. Rodgers, Helen Q. Huang, David Cella, David M. O'Malley, Daron G. Street, Krishnansu S. Tewari, David P. Bender, Robert T. Morris, William J. Lowery, David S. Miller, Summer B. Dewdney, Nick M. Spirtos, Shashikant B. Lele, Saketh Guntupalli, Frederick R. Ueland, Gretchen E. Glaser, Robert S. Mannel, Philip J. DiSaia
Publikováno v:
Journal of Clinical Oncology. 40:4119-4128
PURPOSE To compare taxane maintenance chemotherapy, paclitaxel (P) and paclitaxel poliglumex (PP), with surveillance (S) in women with ovarian, peritoneal, or fallopian tube (O/PC/FT) cancer who attained clinical complete response after first-line pl
Autor:
John K, Chan, Chunqiao, Tian, Joshua P, Kesterson, Michael T, Richardson, Ken, Lin, Krishnansu S, Tewari, Thomas, Herzog, Daniel S, Kapp, Bradley J, Monk, Yovanni, Casablanca, Parviz, Hanjani, Robert M, Wenham, Joan, Walker, Leah, McNally, Larry J, Copeland, Sharon, Robertson, Samuel, Lentz, Nick M, Spirtos, Jeffery G, Bell
Publikováno v:
Gynecologic Oncology. 167:429-435
To determine the clinical and prognostic significance of CA-125 trends prior to, during, and after chemotherapy in high-risk early-stage epithelial ovarian cancer patients.All patients were enrolled in a phase III randomized trial (GOG 157) following
Autor:
Benoit You, Christopher Purdy, Larry J. Copeland, Elizabeth M. Swisher, Michael A. Bookman, Gini Fleming, Robert Coleman, Leslie M. Randall, Krishnansu S. Tewari, Bradley J. Monk, Robert S. Mannel, Joan L. Walker, Fabio Cappuccini, David Cohn, Mahvish Muzaffar, David Mutch, Andrea Wahner-Hendrickson, Lainie Martin, Olivier Colomban, Robert A. Burger
Publikováno v:
Journal of Clinical Oncology. 40:3965-3974
PURPOSE In patients with high-grade ovarian cancer, predictors of bevacizumab efficacy in first-line setting are needed. In the ICON-7 trial, a poor tumor intrinsic chemosensitivity (defined by unfavorable modeled cancer antigen-125 [CA-125] ELIMinat